| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Sep, 2023 | Jun, 2023 |
| Sales | 6,539 | 6,027 | 5,344 | 4,520 | 3,239 |
| Sales Growth | +8.50% | +12.78% | +18.23% | +39.55% | +17.78% |
| Net Income | -2,689 | -687 | -6,581 | -7,235 | -1,727 |
| Net Income Growth | -291.41% | +89.56% | +9.04% | -318.93% | +39.40% |
Bioharvest Sciences Inc (BHSC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Fiscal Year End Date: 12/31